For the year ending 2025-12-31, EVFM made $20,183K in revenue. $274K in net income. Net profit margin of 1.36%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Product sales, net | 20,183 | 19,363 | ||
| Cost of goods sold | 4,617 | 3,834 | ||
| Gain on change in accounting estimates on contingent royalty liability (note 7) | 1,933 | - | ||
| Amortization of intangible asset | 499 | 619 | ||
| Research and development, net | -3,447 | - | ||
| Selling and marketing | 9,682 | 9,176 | ||
| Research and development | - | 1,845 | ||
| General and administrative | 7,393 | 11,565 | ||
| Total operating expenses | 16,811 | 27,039 | ||
| Income (loss) from operations | 3,372 | -7,676 | ||
| Interest income | 15 | 16 | ||
| Gain on debt extinguishment, net | - | 977 | ||
| Loss on issuance of financial instruments | - | -3,300 | ||
| Other expense, net | 2,635 | 2,575 | ||
| Change in fair value of financial instruments | -359 | 3,698 | ||
| Total other expense, net | -2,979 | -1,184 | ||
| Income (loss) before income tax expense | 393 | -8,860 | ||
| Income tax expense | 2 | - | ||
| Net income (loss) | 391 | -8,860 | ||
| Convertible preferred stock deemed dividends | 117 | -105 | ||
| Net income (loss) attributable to common stockholders | 274 | -8,965 | ||
| Basic EPS | 0 | -0.12 | ||
| Diluted EPS | 0 | -0.12 | ||
| Basic Average Shares | 123,657,915 | 75,195,615 | ||
| Diluted Average Shares | 6,421,746,555 | 75,195,615 | ||
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)